Oxurion NV (OXUR.BR)

EUR 0.09

(4.53%)

Net Income Summary of Oxurion NV

  • Oxurion NV's latest annual net income in 2023 was -18.96 Million EUR , up 40.13% from previous year.
  • Oxurion NV's latest quarterly net income in 2024 Q2 was -3.02 Million EUR , down 0.0% from previous quarter.
  • Oxurion NV reported an annual net income of -31.68 Million EUR in 2022, down -8.67% from previous year.
  • Oxurion NV reported an annual net income of -29.15 Million EUR in 2021, down -4.09% from previous year.
  • Oxurion NV reported a quarterly net income of -10.62 Million EUR for 2023 Q2, down 0.0% from previous quarter.
  • Oxurion NV reported a quarterly net income of -8.34 Million EUR for 2023 Q4, down 0.0% from previous quarter.

Annual Net Income Chart of Oxurion NV (2023 - 2006)

Historical Annual Net Income of Oxurion NV (2023 - 2006)

Year Net Income Net Income Growth
2023 -18.96 Million EUR 40.13%
2022 -31.68 Million EUR -8.67%
2021 -29.15 Million EUR -4.09%
2020 -28.01 Million EUR 45.95%
2019 -51.82 Million EUR -34.71%
2018 -38.47 Million EUR -268.83%
2017 22.78 Million EUR 137.78%
2016 -60.31 Million EUR -59.21%
2015 -37.88 Million EUR 25.88%
2014 -51.11 Million EUR -293.61%
2013 26.4 Million EUR -13.2%
2012 30.41 Million EUR 240.57%
2011 -21.63 Million EUR -55.19%
2010 -13.94 Million EUR 0.91%
2009 -14.07 Million EUR -216.33%
2008 12.09 Million EUR 175.75%
2007 -15.96 Million EUR -57.56%
2006 -10.13 Million EUR 0.0%

Peer Net Income Comparison of Oxurion NV

Name Net Income Net Income Difference
Nicox S.A. -20.88 Million EUR 9.157%
European Medical Solutions -709 Thousand EUR -2575.458%
FERMENTALG -14.14 Million EUR -34.075%
argenx SE -272.91 Million EUR 93.049%
BioSenic S.A. -28.77 Million EUR 34.085%
Celyad Oncology SA -8.44 Million EUR -124.538%
Hyloris Pharmaceuticals SA -15.38 Million EUR -23.336%
Onward Medical N.V. -36.18 Million EUR 47.572%
PHAXIAM Therapeutics S.A. -23.48 Million EUR 19.24%
Financière de Tubize SA 88.15 Million EUR 121.519%
UCB SA 343 Million EUR 105.53%